Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
The standard of care for EGFR-mutated non-small cell lung cancer is shifting beyond single-agent osimertinib, with two combination strategies now showing superior survival outcomes. One pairs osimertinib with chemotherapy; the other combines lazertinib with amivantamab, delivering one of the largest survival gains ever seen in this setting — about 12 months. The catch? Both come with added toxicity, making individualized, shared decision-making more important than ever.
For years, osimertinib (Tagrisso) was the go-to first-line treatment for EGFR-mutated non-small cell lung cancer (NSCLC). But the landscape is shifting fast. Two combination strategies have now demonstrated superior outcomes over osimertinib alone, prompting oncologists to weigh meaningful survival gains against real-world toxicity and treatment burden.
The first approach, from the phase 3 FLAURA2 trial, adds chemotherapy to osimertinib — a toxicity profile most oncologists are already familiar with. The second, from the phase 3 MARIPOSA trial, combines lazertinib (Lazcluze) with amivantamab (Rybrevant), a bispecific antibody targeting EGFR and MET. This regimen delivered roughly 12 months of additional survival benefit — one of the largest ever seen in EGFR-mutated lung cancer — though it comes with challenging side effects like paronychia, rash, and diarrhea. Proactive mitigation strategies are being explored in the ongoing COCOON and SKIPPirr trials.
Key Takeaways:
Why it matters: With multiple effective options now available, the challenge isn't just efficacy — it's matching the right regimen to the right patient. Oncologists must invest more time in nuanced conversations to ensure patients truly benefit from these advances.
